UBS MSCI Switzerland 20/35 UCITS ETF(CHF)A-dis is a equity ETF from UBS tracking the UBS Lux Fund Solutions – MSCI Switzerland 20/35 index through physical replication. Domiciled in Luxembourg and launched in 2013, the fund manages about 667 M € and charges a TER of 0.20% — 20 € per year on a €10,000 investment. Income is paid out to investors periodically (distributing).
UBS MSCI Switzerland 20/35 UCITS ETF(CHF)A-dis competes with 6 other products on the same index (UBS Lux Fund Solutions – MSCI Switzerland 20/35): it ranks 2nd by fund size and 1st by ongoing cost, with a TER of 0.20% against a group median of 0.20%. It has been listed since 2013, 13 years of track record — the oldest in its comparison group.
On a €10,000 investment the TER costs 20 € a year. The cheapest of the group is UBS MSCI Switzerland 20/35 UCITS ETF(CHF)A-acc at 0.20%, or 20 € on the same amount: a difference of 0 € every year, roughly 0 € over ten years before compounding.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 74.7% of the portfolio.
Income is distributed periodically: it produces cash flow, but reinvesting it is up to you if the goal is capital growth. The fund is denominated in CHF. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Luxembourg, which determines the tax treatment of income received by the fund and the supervisory authority.
| Roche Holding AG | 14.0% |
| Novartis AG | 13.9% |
| Nestle S.A. | 12.8% |
| ABB Ltd | 8.2% |
| UBS Group AG | 7.6% |
| Compagnie Financière Richemont SA | 6.0% |
| Zurich Insurance Group AG | 5.4% |
| Lonza Group AG | 2.3% |
| Swiss Re AG | 2.3% |
| Holcim AG | 2.2% |
| SIX Swiss Exchange | SW2CHA | CHF |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.